CO2023009313A2 - Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades - Google Patents

Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades

Info

Publication number
CO2023009313A2
CO2023009313A2 CONC2023/0009313A CO2023009313A CO2023009313A2 CO 2023009313 A2 CO2023009313 A2 CO 2023009313A2 CO 2023009313 A CO2023009313 A CO 2023009313A CO 2023009313 A2 CO2023009313 A2 CO 2023009313A2
Authority
CO
Colombia
Prior art keywords
disease
diseases
treatment
indazole derivatives
irak4 inhibitors
Prior art date
Application number
CONC2023/0009313A
Other languages
English (en)
Inventor
Zhili Xin
Emily Anne Peterson
Ryan Evans
Fang Gao
Philippe Bolduc
Magnus Pfaffenbach
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of CO2023009313A2 publication Critical patent/CO2023009313A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se relaciona con derivados de 2H-indazol de fórmula (I), o sales farmacéuticamente aceptables de estos, (I), en los que todas las variables son como se definen en la memoria descriptiva, capaces de modular la actividad de IRAK4. La divulgación proporciona además métodos para su preparación, para su uso médico, en particular para su uso en el tratamiento y manejo de enfermedades o trastornos que incluyen enfermedad inflamatoria, enfermedad autoinmunitaria, cáncer, enfermedad cardiovascular, una enfermedad del sistema nervioso central, enfermedad de la piel, una enfermedad y afección oftálmica y una enfermedad de los huesos.
CONC2023/0009313A 2020-12-22 2023-07-13 Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades CO2023009313A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063128967P 2020-12-22 2020-12-22
PCT/US2021/064651 WO2022140415A1 (en) 2020-12-22 2021-12-21 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease

Publications (1)

Publication Number Publication Date
CO2023009313A2 true CO2023009313A2 (es) 2023-08-28

Family

ID=80854518

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0009313A CO2023009313A2 (es) 2020-12-22 2023-07-13 Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades

Country Status (11)

Country Link
EP (1) EP4267566A1 (es)
JP (1) JP2024501281A (es)
KR (1) KR20230134499A (es)
CN (1) CN116940572A (es)
AU (1) AU2021409544A1 (es)
CA (1) CA3203011A1 (es)
CO (1) CO2023009313A2 (es)
CR (1) CR20230318A (es)
IL (1) IL303931A (es)
MX (1) MX2023007510A (es)
WO (1) WO2022140415A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152349A1 (en) * 2022-02-14 2023-08-17 Astrazeneca Ab Irak4 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR20180025896A (ko) * 2015-07-15 2018-03-09 오리진 디스커버리 테크놀로지스 리미티드 Irak-4 저해제로서 인다졸 및 아자인다졸 화합물
EP3911652A1 (en) * 2019-01-18 2021-11-24 Biogen MA Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
MX2021015499A (es) * 2019-06-27 2022-04-20 Biogen Ma Inc Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.
EP3990454A1 (en) * 2019-06-27 2022-05-04 Biogen MA Inc. Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of disease

Also Published As

Publication number Publication date
AU2021409544A1 (en) 2023-07-06
KR20230134499A (ko) 2023-09-21
WO2022140415A1 (en) 2022-06-30
CN116940572A (zh) 2023-10-24
MX2023007510A (es) 2023-09-08
EP4267566A1 (en) 2023-11-01
CR20230318A (es) 2023-10-05
IL303931A (en) 2023-08-01
JP2024501281A (ja) 2024-01-11
AU2021409544A9 (en) 2024-02-08
CA3203011A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
CO2022000657A2 (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
CO2022000659A2 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
CL2021001575A1 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
CO2023009316A2 (es) Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades
CO2017000912A2 (es) Derivados de 2 -h indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CO2023015037A2 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
EA202091450A1 (ru) Производные 2h-индазола в качестве ингибиторов cdk4 и cdk6 и их терапевтические применения
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
CO2023009313A2 (es) Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
BR112013003682A2 (pt) métodos para tratar doenças neurodegenerativas
UY37379A (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
ECSP22083772A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CO2022008606A2 (es) Derivados de piridopirimidinona como antagonistas de ahr
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
CO2023001509A2 (es) Cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-
AR122059A1 (es) Usos y formulaciones de cannabinoides
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme
UY39600A (es) Inhibidores del receptor del factor de crecimiento epidérmico
PA8675301A1 (es) DERIVADOS DE (SULFAMOIL-ALQUIL)-AMIDA DE ÁCIDO HETEROARIL-CARBOXÍLICO COMO INHIBIDORES DEL FACTOR Xa.
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR122608A1 (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos usando harryflintia acetispora